Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CADL

Candel Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CADL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Candel Therapeutics, Inc. (NASDAQ: CADL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:26 UTC.

What Candel Therapeutics, Inc. does

The company is a clinical stage biopharmaceutical firm developing off-the-shelf viral immunotherapies designed to trigger anti-tumor immune responses in cancer patients. The company has established two platforms using genetically modified adenovirus and herpes simplex virus constructs, with its most advanced product candidate being aglatimagene, an adenovirus therapy administered with the prodrug valacyclovir.

Summarized from Candel Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-39.39%

Revenue, margins & earnings

FY2021: net loss $36M on revenue $125,000$125,000FY2021FY2022: net loss $19M on revenue $125,000$125,000FY2022
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02DirectorStock Option (Right to Buy)Award1,325$11.5K
  • 2026-10-02DirectorStock Option (Right to Buy)Award380$3.3K
  • 2026-10-02DirectorStock Option (Right to Buy)Award2,189$19.0K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Candel Therapeutics, Inc. do?

The company is a clinical stage biopharmaceutical firm developing off-the-shelf viral immunotherapies designed to trigger anti-tumor immune responses in cancer patients.

When did CADL last file with the SEC?

Candel Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:26 UTC. This page is also available as JSON at /api/data?ticker=CADL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CADL and 5,000+ tickers.

Create a free account — keep CADL
For your agent
GET /api/data?ticker=CADL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt